Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. FUJIFILM Holdings Corporation
  6. News
  7. Summary
    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan

10/21/2020 | 11:50pm EDT

TOKYO, Oct 22 (Reuters) - Japan's Fujifilm Holdings Corp said on Thursday it has partnered with Shanghai-based Carelink Pharmaceutical Co to seek approval in China for Avigan to treat COVID-19 and influenza.

Carelink will use Fujifilm's data on Avigan's treatment of novel coronavirus infections and influenza to seek imported drug approval in China, Fujifilm said in a statement. The two companies also plan to develop an injectable form of the drug.

Fujifilm said last week it was seeking approval for Avigan as a treatment for COVID-19 in Japan. That followed results from a late-stage study in Japan that showed the antiviral drug reduced recovery time for patients with non-severe symptoms.

Avigan, originally developed as an emergency flu drug and known generically worldwide as favipiravir, has been approved in India and Russia to treat COVID-19.

Fujifilm sold global rights in July on Avigan to India's Dr Reddy's Laboratories and Dubai-based Global Response Aid. That deal excluded China, Japan and Russia.

Last month, Fujifilm said the late-stage study of 156 COVID-19 patients in Japan showed that symptoms of those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group.

Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were found to be statistically significant. (Reporting by Rocky Swift; Editing by Christian Schmollinger and Muralikumar Anantharaman)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LIMITED -2.17% 5288.3 End-of-day quote.1.62%
FUJIFILM HOLDINGS CORPORATION -1.23% 7862 End-of-day quote.44.58%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) -0.30% 72.2252 Delayed Quote.-1.80%
All news about FUJIFILM HOLDINGS CORPORATION
06/14FUJIFILM  : North America Corporation, Graphic Systems Division Welcomes Packagi..
AQ
06/11FUJIFILM  : 'Art as an Essential Facet of Life and Community' - Fujifilm Announc..
AQ
06/09FUJIFILM  : Direct Edge Expands Capabilities, Increases Efficiencies, and Deligh..
AQ
05/31FUJIFILM  : Notice of Convocation
PU
05/27FUJIFILM  : Wako Pure Chemical launches “E484Q mutation detection kit&rdqu..
PU
05/24FUJIFILM  : Showcases Comprehensive Portfolio of Enterprise Imaging Solutions at..
AQ
05/18FUJIFILM  : Japan's Fujifilm says it can make new coronavirus variant detection ..
RE
05/18BAYER  : BlueRock, Fujifilm Cellular Dynamics to Co-Develop Cell Therapies for E..
MT
05/18FUJIFILM  : BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therape..
PU
05/17FUJIFILM  : unit launches COVID-19 detection kit for Indian, Californian variant..
RE
More news
Financials
Sales 2021 2 179 B 19 772 M 19 772 M
Net income 2021 153 B 1 392 M 1 392 M
Net Debt 2021 170 B 1 543 M 1 543 M
P/E ratio 2021 20,0x
Yield 2021 1,25%
Capitalization 3 143 B 28 493 M 28 516 M
EV / Sales 2021 1,52x
EV / Sales 2022 1,37x
Nbr of Employees 73 906
Free-Float 73,9%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 7 935,71 JPY
Last Close Price 7 862,00 JPY
Spread / Highest target 27,2%
Spread / Average Target 0,94%
Spread / Lowest Target -21,1%
EPS Revisions
Managers and Directors
NameTitle
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kunitaro Kitamura Independent Outside Director
Tatsuo Kawada Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
FUJIFILM HOLDINGS CORPORATION44.58%28 493
ABBOTT LABORATORIES1.95%195 557
MEDTRONIC PLC6.89%168 202
BECTON, DICKINSON AND COMPANY-3.98%69 878
HOYA CORPORATION0.11%48 576
ALIGN TECHNOLOGY, INC.14.77%47 450